» Articles » PMID: 40007918

The Anti-Cancer Effects of Arborinine from Ruta Graveolens L. on Michigan Cancer Foundation-7 (MCF-7) Breast Cancer Cells: Inhibition of Cell Growth and Induction of Apoptosis

Overview
Journal Cureus
Date 2025 Feb 26
PMID 40007918
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Arborinine, a plant-derived alkaloid, has shown potential cytotoxic effects against various cancer cell lines. This study aims to evaluate the cytotoxicity and apoptosis effects of arborinine on breast cancer (Michigan Cancer Foundation-7 (MCF-7)) and human embryonic kidney (HEK293) as normal cell lines.

Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to assess the inhibitory concentration of 50% (IC50) after 24 and 48 hours of treatment of HEK293 and MCF-7 cell lines with arborinine. Apoptosis was evaluated through Annexin V/PI staining, and gene expressions including BAX, BCL-2, P53, PARP, and caspases (i.e., 3, 8, and 9) were analyzed via quantitative real-time polymerase chain reaction (qRT-PCR). Additionally, intracellular reactive oxygen species (ROS) levels were measured using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence.

Results: The MTT assay results indicated a dose-dependent reduction in cell viability for both HEK293 and MCF-7 cells following treatment with arborinine. The viability of HEK293 cells decreased significantly (P=0.038) at concentrations above 150 µg/mL, while IC50 for MCF-7 cells was 50 µg/mL and 25 µg/mL for 24 and 48 hours, respectively. Annexin V staining revealed apoptosis rates of 9.36% in untreated MCF-7 cells, increasing to 52.3% post-treatment. Arborinine treatment upregulated pro-apoptotic factors, including BAX, PARP, and P53, while downregulating BCL-2. Additionally, arborinine increased ROS levels by approximately 1.3-fold and decreased glutathione (GSH) levels, while enhancing superoxide dismutase (SOD) activity.

Conclusion: This study shows that arborinine reduces cell viability and induces apoptosis in MCF-7 breast cancer cells by modulating key apoptotic pathways. Its effectiveness at lower concentrations in cancerous cells highlights its potential as a promising therapeutic agent in oncology.

References
1.
Lane D . p53 and human cancers. Br Med Bull. 1994; 50(3):582-99. DOI: 10.1093/oxfordjournals.bmb.a072911. View

2.
Noulala C, Ouete J, Atangana A, Mbahbou G, Fotso G, Stammler H . Soyauxinine, a New Indolopyridoquinazoline Alkaloid from the Stem Bark of Engl. (Rutaceae). Molecules. 2022; 27(3). PMC: 8838469. DOI: 10.3390/molecules27031104. View

3.
Roseghini R, Moreira P, Vale V, Pinheiro A, Costa J, Bittencourt T . Different effects of arborinine alkaloid obtained from Brazilian Erthela baihensis on spleen and thymus cells stimulated in vitro with different mitogens. Immunopharmacol Immunotoxicol. 2006; 28(2):361-76. DOI: 10.1080/08923970600809579. View

4.
Chu Y, Xiao Z, Jing N, Yan W, Wang S, Ma B . Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells. Invest New Drugs. 2020; 39(3):627-635. DOI: 10.1007/s10637-020-01016-y. View

5.
Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View